Scarica l'app Stockscreener
15.61
0.90%
0.14
Pre-mercato:
15.90
0.29
+1.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia to Acquire Kezar via $6.955-Per-Share Cash Tender Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
How Aurinia Pharmaceuticals Inc (AUPH) Affects Rotational Strategy Timing - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (AUP.TO) Competitors - Meyka
Aurinia Pharmaceuticals (AUPH) COO Ryan Cole becomes SEC Form 3 insider - Stock Titan
Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3 - Stock Titan
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
JPMorgan Chase & Co. Grows Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
EBIT per share of Aurinia Pharmaceuticals Inc. – LSE:0UJF - TradingView
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - contractpharma.com
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - TipRanks
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - Stock Titan
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors - Sahm
Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)? - finance.yahoo.com
Investors - Aurinia Pharmaceuticals Inc.
Mutiny at Aurinia Pharmaceuticals? Biotech rallies on C-suite shake-up - MSN
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance (NASDAQ:AUPH) - Seeking Alpha
AUPH Should I Buy - Intellectia AI
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study - ChartMill
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround - Stocktwits
AURINIA PHARMACEUTICALS PB Ratio: 3.29 — 11% Below Median - GuruFocus
The Escalator: Aurinia Pharmaceuticals, Abivax, Ogilvy Health and more - Medical Marketing and Media
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets - MSN
[SCHEDULE 13D/A] Aurinia Pharmaceuticals Inc. Amended Major Shareholder Report - Stock Titan
AUPH SEC FilingsAurinia Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Aurinia Resets Leadership And Capital Plans As Valuation Gap Persists - Sahm
Aurinia names board chair Kevin Tang as new CEO By Investing.com - Investing.com Canada
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up - Investor's Business Daily
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):